The Technical Analyst
Palatin Technologies Inc [PTN]
Exchange: AMEX Sector: Healthcare Industry: Biotechnology
Palatin Technologies Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.53% $1.900
America/New_York / 19 apr 2024 @ 13:11
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 30.66 mill |
| EPS: | -2.98 |
| P/E: | -0.640 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 16.14 mill |
| Avg Daily Volume: | 0.711 mill |
| RATING 2024-04-19 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.640 | sector: PE -4.07 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -0.640 | industry: PE -5.55 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.518 (-72.76%) $-1.382 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 1.638 - 2.13 ( +/- 13.10%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-11 | Deveer Robert K Jr | Buy | 6 000 | Common Stock |
| 2024-03-06 | Deveer Robert K Jr | Sell | 1 685 | Common Stock |
| 2024-03-06 | Deveer Robert K Jr | Sell | 7 286 | Common Stock |
| 2024-03-06 | Deveer Robert K Jr | Sell | 200 | Common Stock |
| 2024-03-06 | Deveer Robert K Jr | Sell | 1 808 | Common Stock |
| INSIDER POWER |
|---|
| 46.73 |
| Last 100 transactions |
| Buy: 594 391 | Sell: 320 931 |
Forecast:
14:49 - $1.887
Live Trading Signals (every 1 min)
Forecast
1: 13:19 - $1.889
Forecast 2: 14:09 - $1.881
Forecast 3: 14:49 - $1.887
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.900 (0.53% ) |
| Volume | 0.0965 mill |
| Avg. Vol. | 0.711 mill |
| % of Avg. Vol | 13.57 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For PTN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
PTN
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.
Latest Press Releases
2024-04-08 07:30:00 - Press Release
Palatin Announces Phase 3 Pl9643 Melody-1 Dry Eye Disease (ded) Clinical Data Results Presented At American Society Of Cataract And Refractive Surgery (ascrs) 2024
Positive phase 3 study results included in dr. eric donnenfeld's presentation co-primary symptom endpoint of pain met statistical significance (p
2024-02-28 07:30:00 - Press Release
Palatin Announces Results Of Pl9643 Melody-1 Pivotal Phase 3 Clinical Trial In Patients With Dry Eye Disease (ded)
On an intent-to-treat analysis, co-primary symptom endpoint met , statistical significance (p
2024-02-15 07:30:00 - Press Release
Palatin Reports Second Quarter Fiscal Year 2024 Financial Results And Provides Corporate Update
Palatin's focus is solely on the development of its melanocortin receptor (mcr) system pipeline pl9643 melody-1 pivotal phase 3 study in dry eye disease (ded) – topline data expected in february oral pl8177 phase 2 clinical study in patients with ulcerative colitis – interim analysis expected in 2q calendar year 2024 – topline results expected in 2h calendar year 2024 bmt 701 phase 2 breakout study in patients with diabetic kidney disease – topline results expected in the second quarter of calendar year 2024 obesity: combination of an mcr4 agonist + glucagon like peptide-1 (glp-1) – phase 2 clinical study targeted to start 1q calendar year 2024 male sexual dysfunction: b remelanotide co-formulated with a pde5i for the treatment of ed in patients that do not respond to pde5i monotherapy – phase 2 clinical study targeted to start 1q calendar year 2024 vyleesi® completed asset sale to cosette pharmaceuticals for up to $171 million – $12 million upfront / up to $159 million in sales-based milestones closed on gross proceeds of $15 million in equity teleconference and webcast to be held on february 15, 2024, at 11:00 am et cranbury, n...
2024-02-09 07:30:00 - Press Release
Palatin To Report Second Quarter Fiscal Year 2024 Results; Teleconference And Webcast To Be Held On February 15, 2024
Cranbury, n.j. , feb. 9, 2024 /prnewswire/ -- palatin technologies, inc. (nyse american: ptn) will announce its second quarter fiscal year 2024 operating results on thursday, february 15, 2024, before the open of the u.s. financial markets.
2024-02-05 07:30:00 - Press Release
Palatin Announces Database Lock For Pl9643 Melody-1 Pivotal Phase 3 Clinical Trial In Patients With Dry Eye Disease (ded)
Top-line results expected in february cranbury, n.j. , feb. 5, 2024 /prnewswire/ -- palatin technologies, inc. (nyse american: ptn), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced database lock for its pl9643 melody-1 pivotal phase 3 clinical trial evaluating the safety and efficacy of pl9643 versus vehicle in the treatment of dry eye disease (ded).
Latest News
2024-04-09 10:01:40 - Zacks Investment Research
Palatin (PTN) Up 15% on Results From Dry Eye Disease Study
A late-stage study data shows that treatment with Palatin's (PTN) experimental dry eye disease drug achieved statistically significant and clinically meaningful improvements across multiple symptom endpoints.
2024-02-15 07:49:16 - InvestorPlace
The 3 Best Penny Stocks to Buy in February 2024
Penny stocks will always provide us with investment opportunities in the event that we do not have a completely high buying power and do not want to buy fractional shares. In the large ecosystem of companies that make life in the financial markets, we can always identify good investment opportunities that allow us to add value to our portfolio and our wealth.
2024-02-09 07:30:00 - PRNewsWire
Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024
CRANBURY, N.J. , Feb. 9, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal year 2024 operating results on Thursday, February 15, 2024, before the open of the U.S. financial markets.
2024-02-01 19:09:57 - InvestorPlace
7 Analyst-Backed Stocks With Promising 10-Bagger Potential
Stay on the Internet long enough – and it won't take too long, believe me – and you'll come across voices that blast the virtues of analyst-backed stocks. Ranging anywhere from legitimate concerns to outright conspiracy theories, the suits on Wall Street don't always get the love from retail investors.
2024-01-11 13:38:51 - InvestorPlace
3 Penny Stocks to Buy to Unlock 2,500% Upside Potential
After four long years of volatility and economic uncertainty, there finally appears to be light at the end of the tunnel heading into 2024. As rates start coming down and monetary policy loosens, we could see significant tailwinds for beaten-down penny stocks primed for a rebound.
2023-12-23 17:00:00 - InvestorPlace
Analysts Say 3 Stocks Have a Combined Upside of 3000%
Wall Street analysts can get a bit optimistic with their price targets. So when I see calls for triple-digit upside, I take them with a grain of salt.
2023-11-09 07:30:00 - PRNewsWire
Palatin to Report First Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on November 14, 2023
CRANBURY, N.J. , Nov. 9, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2024 operating results on Tuesday, November 14, 2023, before the open of the U.S. financial markets.
2023-09-29 20:31:02 - Seeking Alpha
Palatin Technologies, Inc. (PTN) Q4 2023 Earnings Call Transcript
Palatin Technologies, Inc. (NYSE:PTN ) Q4 2023 Earnings Conference Call September 28, 2023 11:00 AM ET Company Participants Carl Spana - President and Chief Executive Officer Steve Wills - Executive Vice President, Chief Financial Officer and Chief Operating Officer Conference Call Participants Joseph Pantginis - H.C. Wainwright & Co., LLC Michael Higgins - Ladenburg Thalmann & Co. Inc. Operator Greetings, and welcome to Palatin's Fourth Quarter and Fiscal Year End 2023 Operating Results Conference Call.
2023-09-22 16:00:00 - PRNewsWire
Palatin to Report Fourth Quarter and Fiscal Year End 2023 Results; Teleconference and Webcast to be held on September 28, 2023
CRANBURY, N.J. , Sept. 22, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2023 operating results on Thursday, September 28, 2023, before the open of the U.S. financial markets.
2023-05-16 09:53:21 - Zacks Investment Research
Palatin Technologies, Inc. (PTN) Reports Q3 Loss, Tops Revenue Estimates
Palatin Technologies, Inc. (PTN) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.75 per share a year ago.